## Edgar Filing: Schuchart Aaron - Form 4

Schuchart A Form 4	aron										
March 01, 2	019										
FORM	14								PPROVAL		
	UNITED	STATES		RITIES A Ashington			COMMISSIO	N OMB Number:	3235-0287		
Check th if no lon subject t Section Form 4 o Form 5 obligatio may con See Instr	rsuant to S (a) of the I	<ul> <li><b>F CHANGES IN BENEFICIAL OWNERSHIP OF</b> <b>SECURITIES</b></li> <li>Section 16(a) of the Securities Exchange Act of 1934, Public Utility Holding Company Act of 1935 or Section ) of the Investment Company Act of 1940</li> </ul>					Estimated burden hou response	Estimated average burden hours per response 0.5			
1(b).											
(Print or Type	Responses)										
1. Name and Address of Reporting Person <u>*</u> Schuchart Aaron			2. Issuer Name <b>and</b> Ticker or Trading Symbol Aeglea BioTherapeutics, Inc. [AGLE]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
				of Earliest T Day/Year) 2019	ransaction		Director X Officer (gi below) Chie		% Owner ner (specify cer		
	(Street)				mendment, Date Original Aonth/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
AUSTIN, 7	TX 78746							More than One R			
(City)	(State)	(Zip)	Tab	ole I - Non-l	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if	Transactio Code (Instr. 8)	4. Securit onAcquired Disposed (Instr. 3,	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect		
Reminder: Re	port on a separate lin	e for each cl	ass of sec	urities bene	ficially ow	ned directly	or indirectly.				
					inforr	nation cont	spond to the collection to the collection of the	n are not	SEC 1474 (9-02)		

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

number.

displays a currently valid OMB control

## Edgar Filing: Schuchart Aaron - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	<ul> <li>Expiration Date (Month/Day/Year)</li> <li>(A)</li> <li>(A)</li> </ul>		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	\$ 8.36	02/28/2019		А	60,000	<u>(1)</u>	02/27/2029	Common Stock	60,000

## **Reporting Owners**

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Schuchart Aaron C/O AEGLEA BIOTHERAPEUTICS, INC. 901 S. MOPAC EXPRESSWAY, SUITE 250 AUSTIN, TX 78746			Chief Business Officer			
Signatures						
/s/ Charles N. York II, by power of attorney	03/01/	2019				
**Signature of Reporting Person	Date	e				

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 28, 2019, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.